Cerity Partners LLC Sells 7,979 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Cerity Partners LLC cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 334,852 shares of the biopharmaceutical company's stock after selling 7,979 shares during the quarter. Cerity Partners LLC owned 0.26% of Halozyme Therapeutics worth $16,356,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of HALO. CBIZ Investment Advisory Services LLC acquired a new position in Halozyme Therapeutics during the 4th quarter worth $29,000. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics in the fourth quarter worth $29,000. Smartleaf Asset Management LLC grew its holdings in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust raised its stake in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Up 0.4 %

Shares of Halozyme Therapeutics stock traded up $0.22 during trading on Tuesday, reaching $61.61. 163,664 shares of the company traded hands, compared to its average volume of 1,407,794. The firm has a market capitalization of $7.61 billion, a PE ratio of 17.96, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a 50 day moving average price of $60.29 and a 200-day moving average price of $54.94. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 503 shares of Halozyme Therapeutics stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares of the company's stock, valued at approximately $2,120,567.40. The trade was a 1.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,200 shares of company stock worth $1,286,568 in the last three months. 2.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on HALO shares. Piper Sandler boosted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Wells Fargo & Company reduced their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Benchmark restated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.